vs

Side-by-side financial comparison of ARTIVION, INC. (AORT) and Jefferson Capital, Inc. (JCAP). Click either name above to swap in a different company.

Jefferson Capital, Inc. is the larger business by last-quarter revenue ($150.8M vs $116.0M, roughly 1.3× ARTIVION, INC.). Jefferson Capital, Inc. runs the higher net margin — 25.4% vs 2.1%, a 23.3% gap on every dollar of revenue. Jefferson Capital, Inc. produced more free cash flow last quarter ($63.0M vs $-7.9M).

Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.

GE Capital was the financial services division of General Electric. Its various units were sold between 2013 and 2021, including the notable spin-off of the North American consumer finance division as Synchrony Financial. Ultimately, only one division of the company remained, GE Energy Financial Services, which was transferred to GE Vernova when General Electric was broken up.

AORT vs JCAP — Head-to-Head

Bigger by revenue
JCAP
JCAP
1.3× larger
JCAP
$150.8M
$116.0M
AORT
Higher net margin
JCAP
JCAP
23.3% more per $
JCAP
25.4%
2.1%
AORT
More free cash flow
JCAP
JCAP
$70.9M more FCF
JCAP
$63.0M
$-7.9M
AORT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
AORT
AORT
JCAP
JCAP
Revenue
$116.0M
$150.8M
Net Profit
$2.4M
$38.4M
Gross Margin
63.1%
Operating Margin
9.2%
46.4%
Net Margin
2.1%
25.4%
Revenue YoY
19.2%
Net Profit YoY
114.7%
EPS (diluted)
$0.06
$0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AORT
AORT
JCAP
JCAP
Q4 25
$116.0M
Q3 25
$113.4M
$150.8M
Q2 25
$113.0M
$152.7M
Q1 25
$99.0M
Q4 24
$97.3M
Q3 24
$95.8M
Q2 24
$98.0M
Q1 24
$97.4M
Net Profit
AORT
AORT
JCAP
JCAP
Q4 25
$2.4M
Q3 25
$6.5M
$38.4M
Q2 25
$1.3M
$47.7M
Q1 25
$-505.0K
Q4 24
$-16.5M
Q3 24
$-2.3M
Q2 24
$-2.1M
Q1 24
$7.5M
Gross Margin
AORT
AORT
JCAP
JCAP
Q4 25
63.1%
Q3 25
65.6%
Q2 25
64.7%
Q1 25
64.2%
Q4 24
63.2%
Q3 24
63.7%
Q2 24
64.6%
Q1 24
64.6%
Operating Margin
AORT
AORT
JCAP
JCAP
Q4 25
9.2%
Q3 25
11.1%
46.4%
Q2 25
7.4%
56.7%
Q1 25
2.2%
Q4 24
2.7%
Q3 24
4.6%
Q2 24
6.6%
Q1 24
26.0%
Net Margin
AORT
AORT
JCAP
JCAP
Q4 25
2.1%
Q3 25
5.7%
25.4%
Q2 25
1.2%
31.2%
Q1 25
-0.5%
Q4 24
-16.9%
Q3 24
-2.4%
Q2 24
-2.2%
Q1 24
7.7%
EPS (diluted)
AORT
AORT
JCAP
JCAP
Q4 25
$0.06
Q3 25
$0.13
$0.59
Q2 25
$0.03
$16.76
Q1 25
$-0.01
Q4 24
$-0.40
Q3 24
$-0.05
Q2 24
$-0.05
Q1 24
$0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AORT
AORT
JCAP
JCAP
Cash + ST InvestmentsLiquidity on hand
$64.9M
$42.3M
Total DebtLower is stronger
$215.1M
Stockholders' EquityBook value
$448.2M
$437.4M
Total Assets
$884.8M
$1.8B
Debt / EquityLower = less leverage
0.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AORT
AORT
JCAP
JCAP
Q4 25
$64.9M
Q3 25
$73.4M
$42.3M
Q2 25
$53.5M
$51.7M
Q1 25
$37.7M
Q4 24
$53.5M
Q3 24
$56.2M
Q2 24
$55.0M
Q1 24
$51.1M
Total Debt
AORT
AORT
JCAP
JCAP
Q4 25
$215.1M
Q3 25
$214.9M
Q2 25
$215.6M
Q1 25
$314.7M
Q4 24
$314.3M
Q3 24
$314.0M
Q2 24
$313.6M
Q1 24
$313.3M
Stockholders' Equity
AORT
AORT
JCAP
JCAP
Q4 25
$448.2M
Q3 25
$438.7M
$437.4M
Q2 25
$419.9M
$410.8M
Q1 25
$294.3M
Q4 24
$276.2M
Q3 24
$304.7M
Q2 24
$295.1M
Q1 24
$295.0M
Total Assets
AORT
AORT
JCAP
JCAP
Q4 25
$884.8M
Q3 25
$857.7M
$1.8B
Q2 25
$838.4M
$1.8B
Q1 25
$791.2M
Q4 24
$789.1M
Q3 24
$803.1M
Q2 24
$789.5M
Q1 24
$784.0M
Debt / Equity
AORT
AORT
JCAP
JCAP
Q4 25
0.48×
Q3 25
0.49×
Q2 25
0.51×
Q1 25
1.07×
Q4 24
1.14×
Q3 24
1.03×
Q2 24
1.06×
Q1 24
1.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AORT
AORT
JCAP
JCAP
Operating Cash FlowLast quarter
$19.6M
$63.1M
Free Cash FlowOCF − Capex
$-7.9M
$63.0M
FCF MarginFCF / Revenue
-6.9%
41.7%
Capex IntensityCapex / Revenue
23.7%
0.1%
Cash ConversionOCF / Net Profit
8.06×
1.64×
TTM Free Cash FlowTrailing 4 quarters
$839.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AORT
AORT
JCAP
JCAP
Q4 25
$19.6M
Q3 25
$22.3M
$63.1M
Q2 25
$15.0M
$130.6M
Q1 25
$-17.0M
Q4 24
$10.1M
Q3 24
$11.5M
Q2 24
$6.1M
Q1 24
$-5.5M
Free Cash Flow
AORT
AORT
JCAP
JCAP
Q4 25
$-7.9M
Q3 25
$17.7M
$63.0M
Q2 25
$11.7M
$130.0M
Q1 25
$-20.6M
Q4 24
$8.7M
Q3 24
$7.8M
Q2 24
$3.6M
Q1 24
$-9.1M
FCF Margin
AORT
AORT
JCAP
JCAP
Q4 25
-6.9%
Q3 25
15.6%
41.7%
Q2 25
10.4%
85.1%
Q1 25
-20.8%
Q4 24
9.0%
Q3 24
8.2%
Q2 24
3.7%
Q1 24
-9.3%
Capex Intensity
AORT
AORT
JCAP
JCAP
Q4 25
23.7%
Q3 25
4.1%
0.1%
Q2 25
2.9%
0.4%
Q1 25
3.7%
Q4 24
1.5%
Q3 24
3.8%
Q2 24
2.6%
Q1 24
3.7%
Cash Conversion
AORT
AORT
JCAP
JCAP
Q4 25
8.06×
Q3 25
3.42×
1.64×
Q2 25
11.16×
2.74×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.73×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AORT
AORT

Aortic Stent Grafts$43.3M37%
On X$27.8M24%
Preservation Services$24.1M21%
Surgical Sealants$20.3M18%
Other Products$463.0K0%

JCAP
JCAP

United States Segment$108.1M72%
Other$35.8M24%
United Kingdom Segment$6.9M5%

Related Comparisons